Lund, Sweden – 9 October 2018 — Camurus (NASDAQ STO: CAMX) invites investors, analysts and media to a Capital Markets and R&D Day in Stockholm on 11 December 2018.
The event will provide updates on Camurus’ key pipeline programs as well as the launch preparations for Buvidal® (CAM2038) in Europe, Australia and the US.
Time: Tuesday 11 December, 1 pm – 4 pm CET
Venue: IVA Conference Center, Grev Turegatan 16, Stockholm
Registration for investors, analysts and journalists
To participate, please register no later than 6 December at CMD@camurus.com
A detailed program will be posted in mid-November on Camurus website www.camurus.com.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Joabsson, VP Business Development
Tel. +46 (0)70 776 17 37
This information was submitted for publication at 08.00 am CET on 9 October 2018.